Gemphire Therapeutics (NASDAQ:GEMP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, November 16th. The brokerage presently has a $10.00 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 12.99% from the stock’s current price.
According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
A number of other research analysts also recently commented on the company. Canaccord Genuity reissued a “buy” rating and issued a $31.00 price target on shares of Gemphire Therapeutics in a report on Monday, October 23rd. Roth Capital initiated coverage on Gemphire Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective on the stock. HC Wainwright began coverage on Gemphire Therapeutics in a research note on Thursday, August 31st. They set a “buy” rating and a $21.00 price objective on the stock. Jefferies Group dropped their price target on Gemphire Therapeutics from $32.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, August 8th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $22.00 target price on shares of Gemphire Therapeutics in a research report on Friday, October 27th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.17.
Gemphire Therapeutics (GEMP) traded down $0.23 during trading on Thursday, hitting $8.85. The company had a trading volume of 22,829 shares, compared to its average volume of 22,834. Gemphire Therapeutics has a 12-month low of $7.20 and a 12-month high of $21.59. The company has a current ratio of 4.17, a quick ratio of 4.17 and a debt-to-equity ratio of 1.00.
Gemphire Therapeutics (NASDAQ:GEMP) last released its earnings results on Monday, November 13th. The company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.14). equities analysts anticipate that Gemphire Therapeutics will post -3.26 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in GEMP. Bamco Inc. NY purchased a new stake in shares of Gemphire Therapeutics during the third quarter worth $2,709,000. Northpointe Capital LLC bought a new position in Gemphire Therapeutics during the second quarter valued at about $3,472,000. Comerica Bank acquired a new stake in shares of Gemphire Therapeutics in the third quarter valued at about $850,000. GM Advisory Group Inc. acquired a new stake in shares of Gemphire Therapeutics in the second quarter valued at about $457,000. Finally, Vanguard Group Inc. grew its position in shares of Gemphire Therapeutics by 137.6% in the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after purchasing an additional 17,892 shares during the last quarter. Institutional investors and hedge funds own 32.11% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/02/gemphire-therapeutics-inc-gemp-raised-to-buy-at-zacks-investment-research.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.